| Ankylosing spondylitis
Enbrel vs Inflectra
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Enbrel vs Inflectra with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInflectra has a higher rate of injection site reactions vs Enbrel based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Inflectra but not Enbrel, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Enbrel
Inflectra
At A Glance
SC injection
Once weekly
TNF-alpha inhibitor
IV infusion
Every 6-8 weeks
TNF-alpha antagonist
Indications
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Psoriasis vulgaris
- Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative
- Juvenile psoriatic arthritis
- Ulcerative Colitis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Arthritis, Psoriatic
- Psoriasis vulgaris
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 50 mg SC once weekly, with or without MTX
Psoriasis vulgaris 50 mg SC twice weekly for 3 months (loading), then 50 mg SC once weekly (maintenance)
Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Factor Negative, Juvenile psoriatic arthritis 0.8 mg/kg SC once weekly, maximum 50 mg per week
Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.
Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.
Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.
Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.
Contraindications
- Sepsis
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)
Adverse Reactions
Most common Infections (upper respiratory tract infection, sinusitis, influenza), injection site reactions (erythema, itching, pain, swelling)
Serious Serious infections (pneumonia, cellulitis, septic arthritis, sepsis), neurologic events, congestive heart failure, hematologic events
Postmarketing Pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, aplastic anemia, congestive heart failure, inflammatory bowel disease, angioedema, autoimmune hepatitis, macrophage activation syndrome, systemic vasculitis, sarcoidosis, lupus-like syndrome, melanoma, non-melanoma skin cancers, Merkel cell carcinoma, convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, uveitis, scleritis, glomerulonephritis, interstitial lung disease, Stevens-Johnson syndrome, toxic epidermal necrolysis, opportunistic infections
Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome
Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma
Pharmacology
Etanercept is a dimeric soluble form of the human p75 TNF receptor that inhibits binding of TNF-alpha and TNF-beta (lymphotoxin alpha) to cell surface TNF receptors, rendering TNF biologically inactive and modulating downstream inflammatory responses including adhesion molecule expression, cytokine levels, and matrix metalloproteinase levels.
Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Enbrel
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (11/12)
Inflectra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Enbrel
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Inflectra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Enbrel
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Inflectra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Enbrel.
$0/fillfill
Inflectra Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EnbrelView full Enbrel profile
InflectraView full Inflectra profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.